MindMed Joins the NASDAQ : MindMed Stock Analysis & Prediction (MMED / MMEDF)
VideosMindMed has officially been added to the NASDAQ Global Market.
On April 22nd, MindMed filed an 8-A12B with the SEC which ultimately allowed it to uplist to the NASDAQ. For NEO owners, the ticker symbol will remain MMED, for OTC owners, it’ll change to MNMD.
On 23rd of April, MindMed announced that as onf April 27th MindMed will be trading as MNMD on the NASDAQ. This means that MindMed was able to meet financial and listing requirements. Typically when securities get listed on major stock exchanges, they are highly traded and prices higher than those that trade OTC. Being able to uplist and trade on an exchange such as the NASDAQ will provide MindMed exposure and visibility to a larger market which might, in the short term, 2, 3 or 4x MindMed’s stock price as more people buy the stock due to FOMO. This happened when Compass Pathways IPOed which almost 4xed its share price within a few days from $17 to $60 before CMPS dropped back down to $33.
Where does MindMed go from here on? MMEDF is just at the beginning of their long-term growth trajectory. Some investors might feel inclined to take profits, which is absolutely understandable. However, like I’ve been saying in the majority of my MindMed episodes or any psychedelic stock videos, the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock
Why the SHROOM BOOM Isn’t Just About Psychedelic Mushrooms
VideosHow mushrooms are taking over the healthcare industry, and how investors can profit off of this. First we will talk about how they are being used as treatments for mental health conditions. And then we will talk about how regular, non psychedelic mushrooms are being used to promote healthy lifestyles, and perhaps even lengthen lifespans and increase quality of life.
The psychedelic craze has overshadowed another important facet of mushrooms and the Shroom Boom.
The health benefits and investing opportunities of non-psychedelic mushrooms.
Fungi like Lion’s Mane, Chaga and reishi have a variety of health benefits, and have recently been labelled as superfoods.
For example, Reishi mushrooms, which have been “revered in Asian societies for thousands of years”, have antibacterial, antiviral, and anti-fungal characteristics, and is high in proteins and vitamins.
While this is great news for you health, and I personally incorporate mushroom extracts into my diet, on this channel we also focuses on investing.
According to the Grand View Research Corporation, the global mushroom market, not including the psychedelic variety, is set to grow to an eye watering $50 billion annually by 2025.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
The Psychedelic Investor was compensated $1,000 by Future Money Trends for the having the interview with PlantX CEO. James (The Psychedelic Investor) does not own a position in PlantX and will not open one for at least 30 days after publication of this video.
Full Disclaimer
https://www.goldstandardir.com/plantx-life-disclaimer-85/
#ShroomBoom #PlantX #PsychedelicStocks
Atai is going PUBLIC! Company Rundown and MindMed Comparison
VideosPowered by Restream https://restream.io/
What's up Psychedelic Investors?!? We have some big news for you. Atai Life Sciences will be going public imminently, directly competing with companies like MindMed (MMED / MMEDF / MMQ) and Numinus (NUMI). This will be a catalyst for the entire sector, and I am excited.
I will be buying some atai when it goes public, how about you?
If you wish to collaborate, send us an email at:
thepsychedelicinvestor@gmail.com
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#AtaiLifeSciences #AtaiIPO #MindMed
Psychedelic Start-Up Atai Life Sciences to Raise $100 Million in IPO, 2nd to List on Nasdaq
BusinessAtai Life Sciences is now the second psychedelic company to list on Nasdaq, with plans to raise $100 million for its IPO.
Digital Therapeutics and Psychedelic Medicines || MindMed ‘s SECRET WEAPON?!?
VideosDigital Therapeutics and Psychedelic Medicines || MindMed's SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai's secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface.
Instead of doing our usual "This Week In Psychedelic Stocks episode", I decided to discuss the article entitled "Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP" as it pertains to MindMed and Atai and because there wasn't a lot of interesting news for our usual Psychedelic segment.
Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there's two reasons.
1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare.
2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology.
I hope you guys found some value in this and I'll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
If you wish to collaborate, send us an email at:
thepsychedelicinvestor@gmail.com
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Time Stamps:
0:00 - Intro
10:08 - Implications for MindMed and Atai
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
Psychedelic Business News Spotlight: April 16, 2021
BusinessThis week in psychedelic business news:psilocybin’s genome sequencing explored, psychedelics meet artificial intelligence, and more.
Psilocybin Trial Treating Depression CRUSHES It [Are We At A Turning Point?]
VideosResults Are OUT! Finally we see that psilocybin is MORE EFFECTIVE in treating depression than the commonly used SSRIS. This study, run by the Imperial College of London is the FIRST MAJOR STUDY directly comparing SSRI’s with psilocybin, the predominant method of treatment.
The data was released on the 14th of April. So yes, this psilocybin trial treating depression CRUSHED SSRIS!
The study had 59 patients with Major Depressive Disorder, 30 of whom took 2 doses of Psilocybin 3 weeks apart, and 29 of whom took an SSRI, and the results will have MASSIVE IMPLICATIONS throughout the psychedelic investing world.
Though the study's primary research objective which was purely by how much depression declined using the Quids SR 16 test, EVERY OTHER MEASUREMENT, such as using other measuring methods, decreases in Suicide ideation and percentage of patients in remission were secondary research objectives.
And again, every secondary research objective heavily FAVORED psilocybin.
This will be major news for companies like Compass Pathways (CMPS) and MindMed (MMED / MMEDF / MMQ)
Link to study: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2032994/suppl_file/nejmoa2032994_appendix.pdf
So that's it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I'll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
...
https://benzinga.grsm.io/thepsychedel
...
General thoughts. We've been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it'll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #psilocybin #shroomboom
GH Research Raises $125 Million to Fund DMT Treatment for Depression
BusinessGH Research closed a $125 million Series B financing round to fund the advancement of its 5-MeO-DMT treatment.
Silo Wellness Expands Shareholder Base to Europe
BusinessToronto's Silo Wellness is now trading on the German Stock Exchange as demand for psychedelic treatments expands.
Daniel Carcillo’s Psychedelic Startup Wesana Health Raises More Funds, On Track to Go Public
Business, CultureFormer NHL player Daniel Carcillo's psychedelic startup Wesana Health is preparing to take the company public.